Related Experiment Video
Updated: Aug 29, 2025

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
Paraneoplastic Cerebellar Degeneration With P/Q-VGCC vs Yo Autoantibodies
Michael Winklehner1, Jan Bauer1, Verena Endmayr1
1From the Division of Neuropathology and Neurochemistry (M.W., V.E., C.S., G.R., R.H.), Department of Neurology, and Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; Department of Electrical and Electronics Engineering (M.M.), Faculty of Engineering, Nagasaki Institute of Applied Science; Department of Neurology and Strokology (S.Y.), Nagasaki University Hospital; Neurology Clinic with Neuromorphomics Laboratory (H.S.), Nitobe Memorial Nakano General Hospital, Tokyo; Division of Surgical Pathology (H.S.), Tokyo Medical and Dental University Hospital; The Center for Personalized Medicine for Healthy Aging (K.I.), Tokyo Medical and Dental University; Departments of Diagnostic Pathology and Clinical Laboratory (Y.T.), Yokosuka Kyosai Hospital, Kanagawa; Department of Neurology (T. Iizuka), Kitasato University School of Medicine, Kanagawa; Department of Neurology and Neurological Science (T.Y.), Graduate School, Tokyo Medical and Dental University; and Department of Neurology (T. Irioka), Yokosuka Kyosai Hospital, Kanagawa, Japan.
Background And Objectives:
Paraneoplastic cerebellar degeneration (PCD) is characterized by a widespread loss of Purkinje cells (PCs) and may be associated with autoantibodies against intracellular antigens such as Yo or cell surface neuronal antigens such as the P/Q-type voltage-gated calcium channel (P/Q-VGCC). Although the intracellular location of the target antigen in anti-Yo-PCD supports a T cell-mediated pathology, the immune mechanisms in anti-P/Q-VGCC-PCD remain unclear. In this study, we compare neuropathologic characteristics of PCD with anti-P/Q-VGCC and anti-Yo autoantibodies in an archival autopsy cohort.
Methods:
We performed neuropathology, immunohistochemistry, and multiplex immunofluorescence on formalin-fixed and paraffin-embedded brain tissue of 1 anti-P/Q-VGCC, 2 anti-Yo-PCD autopsy cases and controls.
Results:
Anti-Yo-PCD revealed a diffuse and widespread PC loss together with microglial nodules with pSTAT1+ and CD8+granzymeB+ T cells and neuronal upregulation of major histocompatibility complex (MHC) Class I molecules. Some neurons showed a cytoplasmic immunoglobulin G (IgG) staining. In contrast, PC loss in anti-P/Q-VGCC-PCD was focal and predominantly affected the upper vermis, whereas caudal regions and lateral hemispheres were spared. Inflammation was characterized by scattered CD8+ T cells, single CD20+/CD79a+ B/plasma cells, and an IgG staining of the neuropil in the molecular layer of the cerebellar cortex and neuronal cytoplasms. No complement deposition or MHC-I upregulation was detected. Moreover, synaptophysin was reduced, and neuronal P/Q-VGCC was downregulated. In affected areas, axonal spheroids and the accumulation of amyloid precursor protein and glucose-regulated protein 78 in PCs indicate endoplasmatic reticulum stress and impairment of axonal transport. In both PCD types, calbindin expression was reduced or lost in the remaining PCs.
Discussion:
Anti-Yo-PCD showed characteristic features of a T cell-mediated pathology, whereas this was not observed in 1 case of anti-P/Q-VGCC-PCD. Our findings support a pathogenic role of anti-P/Q-VGCC autoantibodies in causing neuronal dysfunction, probably due to altered synaptic transmission resulting in calcium dysregulation and subsequent PC death. Because disease progression may lead to irreversible PC loss, anti-P/Q-VGCC-PCD patients could benefit from early oncologic and immunologic therapies.
Related Concept Videos
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...

